ClinicalTrials.gg
WithdrawnNCT03055234Updated Apr 11, 2017

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

A Phase 3 interventional study of Oral Treprostinil and Placebo in Pulmonary Hypertension Associated With Sickle Cell Disease, sponsored by United Therapeutics. Withdrawn. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-04-11.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

This is a multicenter, randomized (2:1; oral treprostinil:placebo), double-blind, placebo-controlled event-driven (time to pulmonary hypertension [PH] clinical worsening) study in subjects with PH associated with sickle cell disease (SCD). Once enrolled, subjects will be evaluated at Weeks 6, 12, 24, and then every 12 weeks for the duration of the study. Subjects will be permitted to enter a 48-week open-label extension period if they experience a PH clinical worsening event.

02

Conditions studied

  • Pulmonary Hypertension Associated With Sickle Cell Disease

Keywords

  • Oral treprostinil
  • 6-Minute Walk Distance
  • PH
  • sickle cell
03

In context

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Lead sponsor

United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must have a diagnosis of SCD confirmed by electrophoresis.
  2. The subject has a diagnosis of symptomatic World Health Organization (WHO) Group 5.1 chronic hemolytic anemia PH.
  3. The subject must have a Baseline 6MWD greater than 150 meters, in the absence of a concurrent injury, illness, or other confounding factor.
  4. The subject has pulmonary function tests conducted within 6 months of Screening or during the Screening period.
  5. The subject must be on stable doses of other medical therapy for at least 30 days prior to randomization with no dose adjustments, additions, or discontinuations.
  6. The subject must be optimally treated with conventional PH therapy for at least 10 days prior to randomization with no additions, discontinuations, or dose changes.
  7. Subjects receiving an endothelin receptor antagonist (ERA) must have been receiving therapy for greater than 90 days, and have reached and maintained a stable dose for a minimum of 30 days prior to randomization.
  8. Subjects receiving calcium channel blockers must have been on a stable dose for a minimum of 3 months prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. The subject is pregnant or lactating.
  2. The subject has previously received oral treprostinil or is receiving a phosphodiesterase type 5 inhibitor (PDE5-I).
  3. The subject has received a prostacyclin within 30 days prior to start of the study, or had previous intolerance or significant lack of efficacy to any prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to titrate that therapy effectively.
  4. The subject has had any other background conventional therapies for PH added, removed, or doses adjusted within 10 days prior to randomization.
  5. The subject has any disease associated with pulmonary arterial hypertension (PAH).
  6. The subject has had a vaso-occlusive crisis, acute chest syndrome event, or unscheduled transfusion within 30 days of randomization.
  7. The subject has a history of ischemic heart disease, including a previous myocardial infarction or symptomatic coronary artery disease, within 6 months prior to Screening or a less than 40% assessed by either multigated angiogram (MUGA), angiography, or echocardiogram.
  8. The subject has (ALT) or aspartate aminotransferase (AST) levels 3 times or greater than the , liver disease/dysfunction, or known Class B or C hepatic disease at Screening.
  9. The subject has chronic renal insufficiency, as defined by the requirement for dialysis.
  10. The subject has a musculoskeletal disorder, any disease that is likely to limit ambulation, or is connected to a machine that is not portable.
  11. The subject has an unstable psychiatric condition or is mentally incapable of understanding the objectives, nature, or consequences of the study, or has any condition which in the Investigator's opinion would constitute an unacceptable risk to the subject's safety.
  12. The subject is receiving an drug, has an investigational device in place, or has participated in an investigational drug or device study within 30 days prior to Screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Oral Treprostinil

    Extended-release oral tablet for three times daily (TID) administration

    Drug: Oral Treprostinil

  • Placebo comparator
    Placebo

    Placebo (sugar pill) for TID administration

    Drug: Placebo

Interventions

  • Extended-release oral tablet for TID administration

  • DrugPlacebo

    Matching placebo for TID administration

06

What researchers measure

Primary outcomes

  1. Effect of oral treprostinil compared with placebo on time to first adjudicated PH clinical worsening (morbidity or mortality) event in subjects with PH associated with SCD

    Clinical worsening is defined as the occurrence of any 1 of the following events: hospitalization related to PH and/or right heart failure, initiation of an infused prostacyclin to treat worsening PH, decrease in 6-Minute Walk Distance (6MWD) \>15% from Baseline directly related to disease under study.

    Time frame: Baseline until the first adjudicated PH clinical worsening event, assessed up to approximately 4 years

Secondary outcomes

  1. Effect of oral treprostinil compared with placebo on exercise capacity as assessed by 6-Minute Walk Distance (6MWD)

    Time frame: Baseline to Week 24

  2. Effect of oral treprostinil compared with placebo on combined 6MWD/Borg dyspnea score

    Time frame: Baseline to Week 24

  3. Effect of oral treprostinil compared with placebo on Borg dyspnea score

    Time frame: Baseline to Week 24

  4. Effect of oral treprostinil compared with placebo on N-Terminal pro-brain natriuretic peptide (NT-proBNP) levels

    Time frame: Baseline to Week 24

  5. Effect of oral treprostinil compared with placebo on maximal tricuspid regurgitant velocity (TRV) assessed by transthoracic Doppler echocardiography

    Time frame: Baseline to Week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2017; primary completion for Dec 2021, 54 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2017
First posted
Feb 16, 2017
StartEst.
Jun 2017
Primary completionEst.
Dec 2021
CompletionEst.
Dec 2022
Last update
Apr 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03055234
Responsible party
Sponsor
First posted
Feb 16, 2017
Start date
Jun 2017 (estimated)
Primary completion
Dec 2021 (estimated)
Completion
Dec 2022 (estimated)
Last update
Apr 11, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion